For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and Tafamidis meglumine represents a genuine change. These groundbreaking therapies stabilize the transthyretin protein, preventing its damaging build-up and reducing the impact of the condition . Individuals are now… Read More